Biomedines

Biomedines is a South Korean biotechnology company specializing in the development of next-generation immune cell therapies for oncology. The company focuses on engineering Chimeric Antigen Receptor (CAR) T-cells and Natural Killer (NK) cells to target both hematologic malignancies and challenging solid tumors. Their proprietary platform aims to enhance the persistence and efficacy of these cells within the immunosuppressive tumor microenvironment. Biomedines' pipeline includes candidates targeting CD19, GPC3, and BCMA, with a strategic goal of developing "off-the-shelf" allogeneic products. The company is positioned to address significant unmet needs in the global cancer treatment landscape through advanced genetic modification and optimized manufacturing.